We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Diagnostics for Respiratory Pathogens

By HospiMedica staff writers
Posted on 21 Dec 2005
A multiplex solid-phase hybridization set of reagents can be used to develop and validate assays for the detection of the sequences of six human respiratory viruses prevalent during the flu season.

The analyte-specific reagents (ASR), called NGEN RVA, can be used to develop assays that can detect the sequences of, and differentiate among, influenza A and B, respiratory syncytial virus, and parainfluenza 1, 2, and 3. More...
The assays can be performed with various sample types, including nasal swabs, and can be used as clinical diagnostic tests. Included with the reagents are a research-use-only real-time polymerase chain reaction (PCR) probe and primer for the identification of the influenza A and B viruses.

The reagents, available from Nanogen, Inc. (San Diego, CA, USA), were developed in cooperation with Prodesse, Inc. (Waukesha, WI, USA), a leading supplier of molecular-based reagents for infectious diseases. The reagents have received the CE Mark.

The reagents target a nucleic acid sequence also found in the H5N1 strain of the influenza, known as the avian flu virus. Labs interested in screening for avian flu can choose between the real-time PCR research reagents or the set of ASRs that can be validated for clinical use.

"Traditionally, labs testing for flu have been limited to choosing between simple rapid tests, which often lack sensitivity and specificity, or culture-based tests that are slow to get results,” noted Howard C. Birndorf, chairman and chief executive officer of Nanogen. "Our advanced molecular-based technologies offer clinical and research labs additional options.




Related Links:
Nanogen

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Bipolar Coagulation Generator
Aesculap
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.